Disease, Disorders, Medical Disciplines

The Max Foundation

Dignity and hope in the face of cancer

Seattle, WA


To increase global access to treatment, care and support for people living with cancer

Notes from the Nonprofit

The Max Foundation is a global health organization that believes that all people living with cancer have the right to access the best treatment and support. Through personalized access services, quality training and education, and global advocacy efforts, we aim to help people face cancer with dignity and hope.

Our services are global and multifaceted. We provide education and training at all levels of the communities in which we work. By partnering with industry, non-governmental agencies, health care providers, and national cancer patient organizations, we are able to support people and provide effective solutions for access to treatment. Through our global advocacy efforts, we work to raise awareness of the disease and draw attention to the needs of people living with cancer.

Every year, our dedicated team helps people in more than 100 countries.

Ruling Year


President and CEO

Pat Garcia-Gonzalez

Main Address

200 NE Pacific Street, Suite 103

Seattle, WA 98105 USA


blood cancer, rare cancer, international, diagnostics, treatment, global health, chronic myeloid leukemia, access





Cause Area (NTEE Code)

Alliance/Advocacy Organizations (G01)

Health Support Services (E60)

Community Health Systems (E21)

IRS Filing Requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2017, 2016 and 2015.
Register now

Social Media

Programs + Results

What we aim to solve New!

By 2030, the World Health Organization projects that the number of new cancer patients diagnosed each year will double to more than 23 million worldwide. But the vast majority of those – 7 out of 10 – will be in low- and middle-income countries (LMICs) where optimal treatment and care is a rarity. For the people in these countries, disproportionate burden and inadequate resources will combine to devastating effect unless new and innovative solutions are developed to bridge the gaps in the availability of cancer treatments.

Our programs

What are the organization's current programs, how do they measure success, and who do the programs serve?

SOURCE: Self-reported by organization

Max Access Solutions

Where we workNew!

Charting Impact

Five powerful questions that require reflection about what really matters - results.

SOURCE: Self-reported by organization

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

How will they know if they are making progress?

What have and haven't they accomplished so far?

The Max Foundations aims to decrease premature mortality from cancer in under-resourced regions of the world by increasing access to treatment, care, and support. Our aim directly aligns with one of the key Sustainable Development Goals set by the United Nations in September of 2015: “By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.”

Achieving our aim means developing innovative treatment access solutions so people diagnosed with cancer in LMICs can gain access to any approved treatment indicated for their disease (i.e. treatments already available to patients in high-income countries) as prescribed by their treating physician. Max Access Solutions, our unique patient-centered model, does exactly that. Max Access Solutions provides a long-term bridge to treatment for individually identified patients who live in countries where the prescribed cancer medicine(s) are not locally available. The model focuses on the patient and his/her needs across the disease spectrum, harnessing the power of multisector collaborations including drug manufacturers, international distributors, diagnostics companies, Ministries of Health, MOH hospitals, cancer centers and other public institutions in recipient countries, local NGOs and patient organizations, as well as a cancer research center in the United States. Our Max Access Solutions model is innovative among donation programs because products are only procured following identification of individual patients in need, avoiding historical concerns of product dumping, drug diversion, and expire of unused drug. It is innovative among cancer control initiatives because it views access to treatment as its core goal from which long-term sustainability will follow.

The Max Foundation’s treatment access innovations began in 2001, when we co-developed the Glivec® International Patient Assistance Program (GIPAP) with Novartis. We’ve administered GIPAP ever since and it has become the most successful cancer-treatment access program in history, providing medicine to more than 70,000 people. Today, Max Access Solutions, we offer eight different cancer medicines in partnership with five different pharmaceutical companies, and distribute those medicines to 98 cancer-treating institutions in 72 countries. Max Access Solutions represents a novel approach to humanitarian access to treatment – an international NGO acts as the clearinghouse for products sourced from multiple manufacturers and channels them to validated cancer centers for individual patients. Our model also provides support with patient tracking, planning and forecasting, diagnostic capabilities and reagents, provider training, and patient education and adherence support.

We will determine progress toward our goal with the following measures: • Increased survival o Increased survival in the countries where we work o Decreased survival inequity between high- and low-income countries o Decreased time between diagnosis and access to treatment • Strengthening of health systems o Strengthening of dispensing practices o Strengthening of planning and forecasting practices o Increased accuracy of prescriptions o Increased investment on the disease area by local stakeholders o Increased access to supportive care including diagnostics • Establishment of validated end-to-end supply chain into the target institutions including removal of regulatory hurdles for importation o Improved accuracy of shipments o Reduction in time from ordering to delivery o Improved efficiency of the supply chain

Since its launch in 2016, Max Access Solutions has already provided access to all targeted cancer medications approved for chronic myeloid leukemia (CML) in some of the world’s lowest-income economies. We are currently supplying more than 15,000 patients in LMICs with more than 4,000,000 daily doses of oral cancer medication each year. Of those 15,000+ patients, 2,000 are newly diagnosed, and 700 are being rescued for the second time by gaining access to next-line treatments for their disease – an offering unique to Max Access Solutions. We’ve executed more than 220 collaboration agreements and established a validated supply chain into 98 cancer-treating institutions in 72 countries. Our Max Access Solution for CML has been the perfect test-case to prove a humanitarian donation program can successfully provide patient-centered access to doctor-prescribed treatments. Next, we plan to take our model and replicate it across other cancers by scaling our global network and supply chain.

External Reviews


The Max Foundation

Fiscal year: Jan 01 - Dec 31

Need more info on this nonprofit?

Need more info on this nonprofit?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2016 and 2015
A Pro report is also available for this organization for $125.
Click here to view a Sample Report.


The people, governance practices, and partners that make the organization tick.

Need more info?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2016 and 2015
A Pro report is also available for this organization for $125.
Click here to see what's included.

Board Leadership Practices

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.

SOURCE: Self-reported by organization


Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?



Has the board conducted a formal, written assessment of the chief executive within the past year?



Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?



Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?



Has the board conducted a formal, written self-assessment of its performance within the past three years?